Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Conceptual Fascial Memory Reset Hypothesis: Mechanobiological Insights into Stacking Fascia as an Ultrasound-Visible Structural Phenotype and the Potential Role of Fascial Hydrorelease.

International journal of molecular sciences·2026
Same author

2024 National Clinical Database annual report by the Japan surgical society.

Surgery today·2026
Same author

Effectiveness of post-mastectomy radiation therapy after breast reconstruction for patients with high-risk breast cancer: A retrospective multicenter cohort study (Reborn study-03).

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Quality of Life and Metabolomics Analysis in Response to Meal Kit Intervention During Perioperative Chemotherapy in Patients with Early-Stage Breast Cancer: Protocol for a Single-Center Phase Ⅱ Randomized Crossover Trial.

JMIR research protocols·2025
Same author

Breast reconstruction-related complications from postmastectomy radiation therapy in stage II-III breast cancer: sub-analysis of a multi-institutional observational study (Reborn-03).

Breast cancer (Tokyo, Japan)·2025
Same author

Diagnosis of Myotonic Dystrophy Based on a History of Grip Myotonia in a 21-Year-Old Woman Undiagnosed for Five Years: A Case Report.

Cureus·2025
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Related Experiment Video

Updated: May 22, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

[Which biomarkers can we use?].

Hiroko Nogi1, Ken Uchida, Tadashi Kobayashi

  • 1Department of Breast and Endocrine Surgery, The Jikei University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 25, 2012
PubMed
Summary
This summary is machine-generated.

Breast cancer subtypes like luminal A, B, HER2-enriched, and basal can be identified using immunohistochemistry markers. These classifications guide treatment and predict prognosis, with new therapies needing novel biomarkers.

More Related Videos

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Related Experiment Videos

Last Updated: May 22, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Context:

  • Gene array testing has identified distinct intrinsic biological subtypes of breast cancer: luminal A, luminal B, HER2-enriched, and basal.
  • These subtypes exhibit varying epidemiological risk factors, natural histories, and responses to therapy.
  • Clinicopathological immunohistochemistry can approximate these subtypes, offering a practical alternative to gene expression arrays.

Purpose:

  • To explore the utility of clinicopathological immunohistochemistry in approximating intrinsic breast cancer subtypes.
  • To highlight the clinical significance of these subtypes in guiding systemic therapy recommendations.
  • To emphasize the role of key biomarkers in subtype classification, prognosis, and predicting treatment response.

Summary:

  • Breast cancer subtypes (luminal A, luminal B, HER2-enriched, basal) are crucial for understanding disease behavior and treatment response.
  • Estrogen receptor, progesterone receptor, HER2, and Ki67 are key immunohistochemical markers for classifying subtypes and predicting outcomes.
  • Accurate subtype classification using accessible methods like immunohistochemistry is essential for personalized systemic therapy.

Impact:

  • Subtype classification via immunohistochemistry facilitates personalized treatment strategies for breast cancer patients.
  • Understanding subtype-specific characteristics improves prognostic accuracy and treatment efficacy.
  • The identification of novel biomarkers is crucial for advancing targeted therapies in breast cancer management.